1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Dr. Reddy's Laboratories Limited
  6. Summary
    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
End-of-day quote Bombay Stock Exchange  -  2022-07-03
4365.70 INR   -0.43%
06/30J. B. Chemicals & Pharmaceuticals Limited agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited for INR 98 million.
CI
06/27Asian ADRs Move Lower in Monday Trading
MT
06/24SUB : Intimation – Settlement Agreement with respect to buprenorphine and naloxone sublingual film - Form 6-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bombay Stock Exchange
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/04/2022 Date
4374.65 4363.3 4399.9 4384.35 4365.7 Last
5663 9625 29291 7577 4995 Volume
+1.33% -0.26% +0.84% -0.35% -0.43% Change
Estimated financial data (e)
Sales 2022 212 B 2 685 M 2 685 M
Net income 2022 28 970 M 367 M 367 M
Net cash position 2022 18 474 M 234 M 234 M
P/E ratio 2022 25,2x
Yield 2022 0,66%
Sales 2023 234 B 2 962 M 2 962 M
Net income 2023 33 409 M 423 M 423 M
Net cash position 2023 34 845 M 441 M 441 M
P/E ratio 2023 21,7x
Yield 2023 0,70%
Capitalization 725 B 9 180 M 9 180 M
EV / Sales 2022 3,33x
EV / Sales 2023 2,95x
Nbr of Employees 24 795
Free-Float 91,5%
More Financials
Company
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products,... 
More about the company
Ratings of Dr. Reddy's Laboratories Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about DR. REDDY'S LABORATORIES LIMITED
06/30J. B. Chemicals & Pharmaceuticals Limited agreed to acquire Portfolio of four paediatri..
CI
06/27Asian ADRs Move Lower in Monday Trading
MT
06/24SUB : Intimation – Settlement Agreement with respect to buprenorphine and naloxone s..
PU
06/24Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio f..
BU
06/24Eton Sells Hospital Products to Dr. Reddy's for Up to $50 Million
DJ
06/24Dr. Reddy's Laboratories Acquires Injectables Portfolio from Eton Pharmaceuticals
MT
06/24Indivior Settles Opioid Addiction Treatment Litigation With Dr. Reddy's
DJ
06/23Dr Reddy's Laboratories Plans Mergers and Acquisitions to Climb Up Ladder
CI
06/22SUB : Investor Day Presentation - Form 6-K
PU
06/21TRANSCRIPT : Dr. Reddy's Laboratories Limited - Analyst/Investor Day
CI
06/21DR REDDY LABORATORIES : Newspaper advertisement - Form 6-K
PU
06/21DR REDDY LABORATORIES : TDS communication sent to shareholders - Form 6-K
PU
06/17Asian ADRs Nudge Higher in Friday Trading
MT
06/16Life Insurance Corporation Raises Stake in Dr. Reddy's Laboratories
MT
06/16Life Insurance Corp. of India Lift Stake in Dr. Reddy's Laboratories to 5.65%
MT
More news
News in other languages on DR. REDDY'S LABORATORIES LIMITED
06/27Les ADR asiatiques baissent dans les échanges de lundi
06/24Dr. Reddy's Laboratories acquiert le portefeuille d'injectables d'Eton Pharmaceuticals
06/23Dr Reddy's Laboratories prévoit des fusions et acquisitions pour gravir les échelons
06/17Les ADR asiatiques en hausse dans les échanges de vendredi
06/14Dr. Reddy's Laboratories obtient l'approbation de la FDA américaine pour un médicament ..
More news
Analyst Recommendations on DR. REDDY'S LABORATORIES LIMITED
More recommendations
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 37
Last Close Price 4 365,70 INR
Average target price 4 948,77 INR
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Erez Israeli Chief Executive Officer
Parag Agarwal Chief Financial Officer
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Mukesh Rathi Chief Digital & Information Officer
Sector and Competitors
1st jan.Capi. (M$)
DR. REDDY'S LABORATORIES LIMITED-11.06%9 221
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782